Nkarta to Participate in an Upcoming Investor Conference
Nkarta to Participate in an Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
加利福尼亚南三藩市，2024年11月26日(GLOBE NEWSWIRE) - 生物制药公司nkarta，Inc. (纳斯达克：NKTX) 宣布，一家生物技术公司开发工程化天然杀伤NK细胞疗法，今天宣布其参加以下投资者会议：
7th Annual Evercore HealthCONx Conference
December 4, 2024
2:10 p.m. ET – fireside chat
第七届evercore HealthCONx大会
2024年12月4日
美国东部时间下午2点10分 - 炉边聊天
A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, , and a replay will be archived on the website for approximately 90 days.
该活动的同时网络直播将在Nkarta网站的投资者版块上提供，并将在网站上存档回放约90天。
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at .
关于Nkarta
nkarta是一家处于临床阶段的生物技术公司，正在推动异基因、现货天然杀伤细胞（NK细胞）疗法的开发。nkarta通过将其细胞扩增和冷冻保存平台与专有的细胞工程技术以及基于CRISPR的基因组工程能力相结合，正在打造未来细胞疗法的管线，旨在为门诊治疗环境提供广泛使用的经过深度治疗活性改造的细胞疗法。欲了解更多信息，请访问该公司的网站。
Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com
Nkarta媒体/投资者联系人：
Greg Mann
Nkarta公司
gmann@nkartatx.com
